Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Acute onset autoimmune hepatitis (AIH) shows acute presentation like acute hepatitis and does not have typical clinicopathological features of AIH. There is no gold standard for making the diagnosis. Therefore, losing the timing of starting immunosuppressive therapy, some of the cases develop into severe or fulminant form and have poor prognosis.
Our aim was to elucidate the efficacy of intravenous glycyrrhizin in decreasing alanine aminotransferase (ALT) level in the early stage of acute onset AIH.
Thirty-one patients were defined as acute onset AIH based on our uniform criteria, and were enrolled in this study. We prospectively treated 17 patients with sufficient doses (100 ml/day) of intravenous glycyrrhizin (SNMC) at an early stage (SNMC group), and treated 14 patients of severe disease with intravenous glycyrrhizin and corticosteroids (CS) (SNMC + CS group). We examined their clinical and biochemical features and treatment responses.
The ALT level could be controlled at an early stage using SNMC with no significant difference compared with SNMC + CS, and responsiveness to the therapy was determined by the disease severity at the time of starting therapy rather than the time duration from onset to therapy. Recovery rate was higher in the SNMC group than in the SNMC + CS group (P = 0.035).
The early introduction of sufficient doses of SNMC might prevent disease progression in patients with acute onset AIH. SNMC can be used safely and be useful for patients with difficult-to-diagnose acute liver disease as an ‘initial’ treatment tool to improve liver inflammation before starting disease-specific treatments.
- Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833.
- Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med. 1968;17:214–223.
- Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology. 1983;85:713–717.
- Crapper RM, Bhathal PS, Mackay IR, et al. “Acute” autoimmune hepatitis. Digestion. 1986;34:216–225. CrossRef
- Amontree JS, Stuart TD, Bredfeldt JE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol. 1989;11:303–307. CrossRef
- Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871. CrossRef
- Porta G, Da Costa Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Ped Gastroenterol Nutrition. 1990;11:138–140. CrossRef
- Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929–938. CrossRef
- Yamamoto S, Maekawa Y, Imamura M, et al. Treatment of hepatitis with antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr. 1958;13:73.
- Suzuki H, Ohta T, Takino T, et al. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Double-blind trial. Asian Med J. 1983;26:423–438.
- Hino K, Miyakawa H, Kondo T, et al. Effects of glycyrrhizin therapy on liver histology in chronic aggressive hepatitis. In: Shikata T, Porcell RH, Uchida T, eds. Viral hepatitis C, D and E. Amsterdam: Excerpta Medica; 1987:295–303.
- Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19:1513–1520. CrossRef
- Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res. 2001;19:31–40. CrossRef
- Maria VAJ, Victorino RMM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology. 1997;26:664–669. CrossRef
- Hennes EM, Zeniya M, Czaja AJ, et al. Simplified diagnostic criteria for autoimmune hepatitis. Hepatology. 2008;48:169–176. CrossRef
- Fujiwara K, Yasui S, Tawada A, et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute onset autoimmune hepatitis. Liver Int. (Epub ahead of print). doi:10.1111/j.1478-3231.2011.02524.x
- Finney RS, Somers GF. The antiinflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol. 1958;10:613–620. CrossRef
- Doll R, Hill ID, Hutton C, et al. Clinical trial of a triterpenoid liquorice compound in gastric and duodenal ulcer. Lancet II. 1962;793–796.
- Pompei R, Flore O, Marccialis MA, et al. Glycyrrhizic acid inhibits virus growth and inactivates virus particles. Nature. 1979;281:689–690. CrossRef
- Crance JM, Lévêque F, Biziagos E, et al. Studies on the mechanism of action of glycyrrhizin against hepatitis A virus replication in vitro. Antiviral Res. 1994;23:63–76. CrossRef
- van Rossum TG, Vulto AG, de Man RA, et al. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12:199–205. CrossRef
- Yang BS, Ma YJ, Wang Y, et al. Protective effect and mechanism of stronger neo-minophagen C against fulminant hepatic failure. World J Gastroenterol. 2007;13:462–466.
- Ikeda T, Abe K, Kuroda N, et al. The inhibition of apoptosis by glycyrrhizin in hepatic injury induced by injection of lipopolysaccharide/D-galactosamine in mice. Arch Histol Cytol. 2008;71:163–178. CrossRef
- Tsubota A, Kumada H, Arase Y, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients. Eur J Gastroenterol Hepatol. 1999;11:1077–1083. CrossRef
- Zhang L, Wang B. Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in Chinese patients with chronic hepatitis B. Hepatol Res. 2002;24:220. CrossRef
- van Rossum TG, Vulto AG, Hop WC, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol. 2001;96:2432–2437. CrossRef
- Fujiwara K, Mochida S, Matsui A, et al. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–657. CrossRef
- Fujiwara K, Fukuda Y, Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute onset autoimmune hepatitis. J Gastroenterol. 2008;43:951–958. CrossRef
- Yasui S, Fujiwara K, Yonemitsu Y, et al. Clinicopathological features of severe and fulminant forms of autoimmune hepatitis. J Gastroenterol. 2011;46:378–390. CrossRef
- Fujiwara K, Nakano M, Yasui S, et al. Advanced histology and impaired liver regeneration are associated with disease severity in acute onset autoimmune hepatitis. Histopathology. 2011;58:693–704. CrossRef
- Fujiwara K, Yasui S, Tawada A, et al. Autoimmune fulminant liver failure in adults. A single Japanese center experience. Hepatol Res. 2011;41:133–141. CrossRef
- Yasui S, Fujiwara K, Yokosuka O. Autoimmune fulminant hepatic failure in chronic hepatitis C during peg-interferon-alfa 2b plus ribavirin treatment showing histological heterogeneity. Dig Liver Dis. (Epub ahead of print). doi:10.1016/j.dld.2011.02.014
- Fujiwara K, Yasui S, Yokosuka O. Efforts at making the diagnosis of acute onset AIH. Hepatology. (Epub ahead of print). doi:10.1002/hep.24331
- Lee WM, Squires RH Jr, Nyberg SL, et al. Acute liver failure: summary of a workshop. Hepatology. 2008;47:1401–1415. CrossRef
- Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5–S10.
- Acharya SK, Dasarathy S, Tandon A, et al. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res. 1993;98:69–74.
- Tandon A, Tandon BN, Bhujwala RA. Clinical spectrum of acute sporadic hepatitis E and possible benefit of glycyrrhizin therapy. Hepatol Res. 2002;23:55–61. CrossRef
- Efficacy of Intravenous Glycyrrhizin in the Early Stage of Acute Onset Autoimmune Hepatitis
Digestive Diseases and Sciences
Volume 56, Issue 12 , pp 3638-3647
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Autoimmune hepatitis
- Acute onset
- Intravenous glycyrrhizin
- Disease severity
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan
- 2. Department of Pathology, Tokyo Women’s Medical University Yachiyo Medical Center, Chiba, 276-8524, Japan